---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-032425"
form_type: "8-K"
ticker: null
cik: "0001358762"
company_name: "REATA PHARMACEUTICALS INC"
filed_at: "2023-07-11T23:59:59+00:00"
generated_at: "2026-06-13T09:55:55.437422+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Reata Pharmaceuticals closes $50M Tranche B loan under $275M facility

## Summary
- Closed $50 million Tranche B loan on July 10, 2023, under $275 million loan agreement.
- Funding triggered by FDA approval of the company's prior approval submission.
- Loan agreement initially entered on May 5, 2023, with BPCR Limited Partnership and BioPharma Credit.

## SEC filing metadata
- accession: 0000950170-23-032425
- form_type: 8-K
- cik: 0001358762
- company_name: REATA PHARMACEUTICALS INC
- filed_at: 2023-07-11T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1358762/000095017023032425/0000950170-23-032425-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1358762/000095017023032425/reta-20230710.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-032425
- JSON: https://secwatch.observer/filing/0000950170-23-032425.json
- Plain text: https://secwatch.observer/filing/0000950170-23-032425.txt

## Key facts
- Debt Financings
  REATA PHARMACEUTICALS INC incurred term loan of $50 million with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC.
  - Instrument: term loan
  - Principal: $50 million
  - Counterparty: BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC
  - Event: incurrence
  source text: On July 10, 2023, the Borrower closed the second Tranche (the Tranche B Loan) of $50 million under the Loan Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1358762/000095017023032425/0000950170-23-032425-index.htm
- Material Agreements
  REATA PHARMACEUTICALS INC entered into Loan Agreement with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC valued at up to $275 million (effective 2023-05-05).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC
  - Value: up to $275 million
  - Effective: 2023-05-05
  source text: On May 5, 2023, we, as the Borrower, and certain of our direct and indirect subsidiaries party thereto from time to time, as the guarantors, entered into a loan agreement (the Loan Agreement) with BPCR Limited Partnership (as a Lender), BioPharma Credit Investments V (Master) LP (as a Lender), and BioPharma Credit PLC, as collateral agent for the Lenders, pursuant to which the Lenders agreed to make term loans to the Borrower in an aggregate amount of up to $275 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1358762/000095017023032425/0000950170-23-032425-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.